St George's Respiratory Questionnaire Score Predicts Outcomes in Patients with COPD: Analysis of Individual Patient Data in the COPD Biomarkers Qualification Consortium Database. by Müllerova, H et al.
141 SGRQ Predicts Outcomes in COPD
journal.copdfoundation.org   JCOPDF © 2017 Volume 4 • Number 2 • 2017
For personal use only. Permission required for all other uses.
Chronic Obstructive Pulmonary Diseases:
Journal of the COPD Foundation
St George’s Respiratory Questionnaire Score Predicts Outcomes 
in Patients with COPD: Analysis of Individual Patient Data in the 
COPD Biomarkers Qualification Consortium Database
Hana Müllerova, PhD1 Heather Gelhorn, PhD2 Hilary Wilson, PhD2 Victoria S. Benson, PhD1  
Niklas Karlsson, PhD3  Shailendra Menjoge, PhD4  Stephen I. Rennard, PhD5,6 Maggie Tabberer, MSc1  
Ruth Tal-Singer, PhD7 Debora Merrill, MBA8 Paul W. Jones, PhD, FRCP, FERS1,9
Background: We aimed to estimate the usefulness of a disease specific health status measure, the St George’s 
Respiratory Questionnaire (SGRQ), to predict outcomes in patients with chronic obstructive pulmonary disease 
(COPD).
Methods: Individual patient-data of 12043 patients from long-term randomized clinical trials (2-4 years’ duration) 
in the COPD Biomarkers Qualification Consortium database were analyzed.  The adverse COPD outcomes were: 
exacerbations of COPD, hospital admissions due to exacerbation and all-cause mortality. Cox proportional hazards 
regression was used to calculate adjusted hazard ratios (HR) and 95% confidence intervals (CIs) for quartiles of 
SGRQ scores at baseline and time to first event, and time from first to second event, where appropriate. 
Results: The risk of adverse COPD outcomes increased with each increasing quartile of SGRQ score for all time 
to first event analyses. When comparing the lowest versus the highest quartile, the event risk (HRs [95% CIs]) 
increased by 40% for exacerbations (1.40 [1.29, 1.51]); 2-fold for hospital admissions (2.01 [1.78, 2.28]) and more 
than 2-fold for all-cause mortality (2.30 [1.91, 2.78]). For second event analyses in a subset of eligible patients, 
these trends persisted albeit with reduced risk estimates for exacerbations. 
Conclusions: Among patients with COPD, health status measured by a SGRQ score predicted exacerbations of 
COPD, hospital admissions due to exacerbations and their recurrence and death after adjustment. These data 
support the rationale for a health status measure use as a drug development tool and suggest that a health status 
measure may also have a role in risk assessment for COPD patients in routine medical care.
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Introduction
Chronic obstructive pulmonary disease (COPD) is 
the third leading cause of death in the United States 
and worldwide.1 COPD is characterized by persistent 
airflow limitation, which is usually of a progressive 
nature.2 In many patients, the course of COPD is 
punctuated by exacerbations.3 Exacerbations of 
COPD can result in hospital admissions, which 
are associated with both high clinical impact on 
patients and substantial economic burden to health 
care systems.4-6 Measures aiming to improve 
quality of care and to reduce hospitalizations have 
been introduced in many health care systems. In the 
United States, targets to reduce readmission before 
30 days have been introduced as a way to improve 
care and reduce direct health care cost.7 Identifying 
patients at high risk of exacerbations of COPD or 
death is therefore of importance for both patients 
and health care providers and administrators.
Patient-reported health status is both an important 
marker of a patient’s well-being and a predictive 
marker for other outcomes, including mortality, 
hospitalizations and rehospitalizations across a 
spectrum of diseases.8-11 Among patients with 
COPD, poorer health status was associated with an 
increased risk of adverse COPD outcomes including 
exacerbations of COPD and mortality, across a 
variety of patient populations and settings, including 
clinical trials and observational studies.3,12,13 
In this analysis, our objective was to expand this 
body of literature by quantifying the relationship 
between baseline health status measured using the 
St George’s Respiratory Questionnaire (SGRQ), and 
COPD outcomes including exacerbations of COPD, 
hospital admission due to exacerbation, recurrent 
exacerbation, recurrent hospital admission due 
to exacerbation and all-cause mortality. This was 
accomplished using a large population of patients 
with COPD identified from an integrated database of 
individual patient data (n=12043) from randomized 
clinical trials between 2 and 4 years in duration that 
were pooled in the COPD Biomarkers Qualification 
Consortium (CBQC) database. The CBQC was 
specifically formed to support the qualification 
of novel and widely recognized endpoints as drug 
development tools in COPD studies.
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Methods
Design and Population
Using a pre-specified analysis plan, we conducted a 
longitudinal analysis using prospectively collected 
individual patient data from 3 long-term (2-4 years) 
randomized controlled trials (RCTs) that had been 
integrated into the CBQC database for SGRQ regulatory 
qualification.  Further details on these clinical trials are 
available in the online data supplement Table S1. The 
overall objectives and design of the CBQC initiative, a 
public-private partnership are described elsewhere.14 
Health Status Measure: St George’s 
Respiratory Questionnaire
The SGRQ was chosen, since it is a well-established 
health status measure used in many interventional and 
observational studies. The minimal important clinical 
difference is estimated as a 4 unit difference or change 
in the SGRQ total score.15 
The baseline SGRQ scores, at study entry, were 
stratified into quartiles in order to improve interpretation 
from a clinical perspective and minimize the effect of 
any potential non-linear relationship between SGRQ 
score and the outcomes of interest. To represent the 
SGRQ score distribution in a broad clinical population 
of patients diagnosed with COPD, the quartiles were 
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Patient Disposition and Selected Baseline 
Characteristics 
Data from 12043 patients with COPD were integrated 
(Figure 1); their mean age was 64.7 years (standard 
deviation [SD] 8.4), 76% were male and on average they 
had severe airflow limitation (mean FEV1 predicted of 
45.0%, SD 12.7%). During the 12-month period prior 
to baseline, 61.3% experienced at least 1 exacerbation 
and 18.1% were admitted to the hospital for COPD. The 
number of patients with data available for analysis per 
each outcome was: exacerbation population, N=8997; 
hospital admission due to exacerbation population, 
N=10562; all-cause death population, N=10850 (Figure 
1).
Distribution of Outcomes of Exacerbations and 
Mortality During Follow-Up by Baseline SGRQ 
Score Quartiles 
Overall, the number of exacerbations per patient and 
mean rate per patient-year in study increased with 
Results
determined using baseline SGRQ scores calculated 
using all the patients in the medium-term studies in 
the integrated database, comprising of long- term RCTs 
and observational studies (total N=19543). Quartiles of 
SGRQ scores were derived as: 1st: <32, 2nd: ≥32 and 
<46, 3rd ≥46 and <60, 4th ≥60, with the first quartile 
representing the best health status.
Other Measures 
Details on age, sex, body mass index (BMI) category, 
World Health Organization (WHO) income category,16 
smoking status (current or past), duration of COPD, 
treatment group (summarized as long-acting 
bronchodilators, inhaled corticosteroid-containing 
medications, and placebo); and the grade of airflow 
limitation based on the value of forced expiratory 
volume (FEV1) in 1 second2 were also available. In 
addition, the year of study initiation was included to 
account for trends in changes in management of COPD 
over time. 
Outcomes
The following outcomes of COPD were evaluated: (a) 
exacerbations of COPD, (b) hospital admissions due to 
COPD, and (c) all-cause mortality. For exacerbations and 
hospital admissions, both first and second events, were 
considered. Exacerbations of COPD were defined based 
on health care utilization, per specific study protocols. 
Events resulting in a COPD patient being managed 
with a prescription for an oral corticosteroid and/or 
antibiotic were classified as moderate exacerbations. 
Hospital admissions due to exacerbations of COPD, 
labeled as severe events, required an admission to a 
hospital with at least 1 overnight stay. 
Statistical Analysis 
This is a post-hoc re-analysis of existing clinical 
trials data. The data analysis plan was approved 
by the CBQC and all participating pharmaceutical 
companies. No further scientific or ethics review and 
approval was required. Data from all patients were 
analyzed independent of their original allocation to an 
intervention with an individual medication; however, 
treatment group (e.g., bronchodilator), was included as 
a covariate in the analysis. 
Summary statistics for each outcome, including event 
count, rate per patient-year in the study and time to event 
in days during follow-up, were calculated. Time to event 
analysis was described using Kaplan-Meier curves. Cox 
proportional hazards models were employed to estimate 
hazard ratios (HRs) and 95% confidence intervals (CIs) 
for the associations between baseline SGRQ scores 
(quartiles) and the risk of experiencing an outcome. All 
analyses were adjusted for age, sex, year of study start 
with reference group of pre-2002 trials, BMI, WHO 
income group, treatment group, COPD duration, airflow 
limitation grade, and smoking status. A test for HRs 
across quartiles using the mid-point for each SGRQ 
quartile and assuming a linear trend was applied.
For analysis of each outcome a specific cohort of 
patients was derived, where patients were excluded 
from the analysis if they had (1) maximum duration 
of inclusion in a study ≤76 days; (2) an outcome that 
occurred ≤ day 76; or, (3) missing information for any 
of the adjustment variables. This decision was made 
based on the observation that there were many missing 
outcomes for patients who had dropped out of the study 
soon after the baseline visit and prior to the common 
time point for study visit 1. The reasons for drop-out 
and the outcomes for these patients were unknown. To 
minimize information bias caused by these missing 
data, records of exacerbation events, or hospitalizations 
occurring prior to day 77 for those participants that had 
a maximum study day more than 76 days, were also 
removed.
Analyses were conducted using SAS 9.4 software.
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worsening baseline SGRQ score quartile (Table 1). 
The number of patients who reported an exacerbation 
increased from 57% (1st quartile: representing best 
health status) to 70% (4th quartile), and the mean 
number of exacerbations increased from 0.60 to 1.03 
events per patient per year. Among those with at least 
1 exacerbation, the overall median time to first event 
was 321 days which decreased with worsening SGRQ 
quartile; the difference between the first and fourth 
quartiles of SGRQ was 76 days (361 days versus 285 
days); survival time to first exacerbation is described 
in Figure S1 in the online data supplement. Among 
patients with more than 1 exacerbation (N=5864), the 
median time from first to second event was also shorter 
with worse SGRQ score; the difference between the first 
and fourth quartiles was 57 days (211 days versus. 154 
days).
Data were available for 10562 patients for the analysis 
of hospital admissions. This sample was larger than the 
exacerbation sample because exacerbations occurred 
more frequently in the ≤ day 76 period, so more cases 
were excluded from the exacerbation analysis. Like 
the exacerbation population, the number of patients 
who reported a hospitalization increased from 16% 
(1st quartile: representing best health status) to 31% 
(4th quartile: worst health status) (Table 2). The mean 
number of events increased from 0.11 
to 0.29 events per patient per year with 
increasing SGRQ quartile. Among 
those with at least 1 event, the time 
to first hospital admission was shorter 
with worse SGRQ score; the difference 
in median number of days between the 
first and fourth quartiles was 89 days 
(532 days versus 443 days); survival 
time to first hospital admission is 
described in Figure S2 in the online 
data supplement. Among patients 
with more than 1 hospital admission 
(N=2477), the time from first to second 
also shortened with increasing SGRQ 
score, with a difference in median 
number of days between the first and 
fourth quartiles of 94 days (270 days 
versus 176 days).
Overall, 10.2% of 10850 patients died 
during the follow-up period. Mortality 
increased with increasing SGRQ 
quartile, from 6.8% in the 1st quartile 
to 14.3% in the 4th quartile; survival time decreased 
with increasing quartile of SGRQ score (Table 2, Figure 
S3 in the online data supplement). 
Risk of COPD Outcomes by Quartile of 
Baseline SGRQ Score
In a multivariable analysis, a significant association 
between worse health status and increased risk of 
exacerbation was observed with each successively 
higher quartile of SGRQ score (trend analysis of HR 
estimates across quartiles, p<0.0001) (Table 3). The 
corresponding risk estimates versus the 1st SGRQ 
quartile of an exacerbation (as HRs [95% CIs]) were 1.19 
[1.11, 1.28] for 2nd quartile, 1.28 [1.19, 1.38] for 3rd 
quartile, and 1.40 [1.29, 1.51] for 4th quartile. The risk 
of a second event also increased with each successive 
increase in quartile of SGRQ score. When compared to 
the first SGRQ quartile, HRs [95% CIs] were 1.18 [1.08-
1.30], 1.20 [1.09-1.32], and 1.26 [1.14-1.40] for 2nd, 3rd, 
and 4th SGRQ quartiles, respectively; trend analysis HR 
estimates across SGRQ quartiles, p<0.0001.
Similarly, the risk of hospital admission due to an 
exacerbation increased with worsening health status 
(Table 3). Each successively higher quartile of SGRQ 
score conferred an increased risk of first hospitalization 
(HRs [95% CIs]) versus 1st quartile: 1.27 [1.11, 1.44] 
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for 2nd quartile, 1.53 [1.35, 1.74] for 3rd quartile and 
2.01 [1.78, 2.28] for 4th quartile; trend analysis for HR 
estimates across SGRQ quartiles p<0.0001. The risk of 
a second hospital admission also increased with poorer 
health status; however, to a lesser degree (Table 3). 
Risk of all-cause mortality was increased more than 
twice among patients with the poorest health status 
compared to those with the best; trend analysis for HR 
estimates across quartiles p<0.0001. The corresponding 
risk estimates (HRs [95% CIs]) versus 1st quartile were: 
1.35 [1.11, 1.64] for 2nd quartile, 1.71 [1.42, 2.07] for 
3rd quartile and 2.30 [1.91, 2.78] for 4th quartile (Table 
3).
Discussion
In this large database of patients with COPD, SGRQ 
scores at study entry predicted exacerbations of 
COPD and their recurrence, hospital admissions due 
to exacerbations, and all-cause death. This predictive 
capacity was independent of a comprehensive set of 
baseline patient demographics and markers of COPD 
severity, including FEV1 and treatment regimen. 
These associations were statistically significant; with 
each successive increase in the quartile of SGRQ 
baseline score, the risk of an adverse COPD outcome 
(exacerbation, hospitalization or death) increased. 
Patients reporting the poorest health status, i.e., 
SGRQ score of 60 or more, had a 40% increased risk 
of experiencing an exacerbation of COPD and a 26% 
increased risk of a recurrent episode compared to those 
with relatively mild impairment (SGRQ<32). Moreover, 
the risk for hospital admissions for COPD was doubled 
in the worst SGRQ quartile (4th quartile) and the risk of 
recurrent admissions was also increased, by 46%. The 
group with the poorest health status had an increased 
risk of death of 2.3-fold relative to patients with the 
best scores. Even patients in the 2nd and 3rd quartiles 
of SGRQ scores were at significantly increased risk 
of adverse events compared to those with the mildest 
impairment of health status (SGRQ score <32).
Unlike hospitalization and all-cause mortality, the 
difference in risk of exacerbations between patients 
in the more severe SGRQ quartiles (2nd-4th quartile) 
was smaller than the difference between patients in 
1st and 2nd quartiles. The reason for this is not clear, 
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but it suggests a floor effect in the capacity of the 
SGRQ to predict exacerbations with any score above 
the mildest degree of health status impairment. SGRQ 
scores predicted both recurrent exacerbations and 
hospitalization, but to a lesser degree compared with 
the risk of any first event. Several factors may drive this 
observation. First, we excluded patients who left the 
study or who experienced 1 of the study outcomes prior 
to Day 76, which was the common time of the first post 
baseline study visit within the CBQC SGRQ database. 
This means that only stable patients were included in 
the analysis. Second, patients often die or are withdrawn 
from studies as the result of their exacerbations and 
hence a survivor bias may have contributed to the 
increase, although to a lower degree of risk of second, 
compared to first events. Finally, the time for which 
individuals were at risk for first events was greater than 
that of second events.
This study is the first large-scale analysis of the 
predictive validity of the SGRQ in COPD. It combined 
data from individual patients participating in 3 
large long-term trials and the size of the analysis 
population is unprecedented in COPD.  The use of data 
obtained in RCTs allowed for a reliable and relatively 
standardized ascertainment of COPD outcomes 
through similar definitions of events used in the 
primary trials. The success of this large-scale analysis 
is the result of a unique public-private partnership 
coordinated by the COPD Foundation (a non-profit 
organization representing patients with COPD) that 
allowed integration of clinical trial datasets across 
several pharmaceutical industry-sponsors working in 
collaboration with academics that provides a model for 
future data integration efforts.14
Several limitations need to be noted in relation to this 
analysis. It did not include results from the observational 
studies that were integrated in the CBQC database 
due to the different outcome definitions and limited 
longitudinal data availability for some of these studies. 
Almost 50% of the clinical trial study populations had 
missing data concerning pre-baseline exacerbations of 
COPD, mainly due to differences in the way these data 
were collected across the trials. This prevented us from 
assessing the effect of prior exacerbations (i.e.,  before 
entry into the trials) on the association between health 
status and COPD outcomes. Since it is known that 
previous exacerbation history is predictive of future 
exacerbations, this is an important limitation.3 Further, 
limited information was available on comorbidities 
of COPD and, hence, these were also not included in 
the model. RCTs often recruit selective samples of the 
clinical population, which may limit the generalizability 
of these observations. To partly mitigate this bias, the 
quartiles of SGRQ baseline score were based on both 
long-term RCTs and observational studies of similar 
duration. The distribution of SGRQ score in this study 
population corresponds closely to that observed in 
a cross-sectional study of 1817 patients with COPD 
recruited from 5 European countries (median SGRQ 
score 44, interquartile range 30-59).17
The findings of the current study suggest that health 
status measurement provides additional prognostic 
information independent of factors such as age, sex, 
smoking status, BMI, income group, duration of COPD 
and airflow limitation and may also be of value in clinical 
practice. However, since the SGRQ was developed for 
specialist and research use, it is likely to be too time 
consuming for routine use in primary care. Newer 
shorter instruments such as the COPD Assessment Test 
(CAT) have been developed to overcome this limitation 
on use of SGRQ.18 CAT correlates well with SGRQ 
scores, and there is also evidence that CAT scores can 
predict exacerbations. It is yet to be determined whether 
the CAT can predict adverse outcomes in the same way 
as the SGRQ.19
Conclusions
Among patients with COPD, a baseline SGRQ score 
is a significant predictor of exacerbations, hospital 
admissions and death. The data support the rationale 
for a health status measure use as a drug development 
tool and suggest that a health status measure should be 
a part of risk assessment for COPD patients in routine 
medical care.  
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